glp-1 drug mounjaro World Health Organization issues first-ever guidelines for use of weight loss medications Mounjaro (Tirzepatide): Raising the Bar

The complete absence of clinical data means there is no way to separate genuine ingredient effects from placebo, seasonal variation, or concurrent lifestyle changes that reviewers may have made

Furthermore, no distinctive biological activities have been attributable specifically to the amidated forms of GLP-1

Mike Haney: So the clinical indication, as I understand it, for getting one of these drugs for the purpose of obesity is a BMI of 30, or a BMI of 27 with another condition like diabetes

The risk-benefit profile of triple agonists remains under investigation

On the central role of mitochondria dysfunction and oxidative stress in alzheimers disease

This is precisely why thorough clinical assessment matters before and during treatment